MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Emergency Medicine Journal

  • September 1, 2026
Foundations of the Initial Trauma Registry in Palestine: A Multicenter Retrospective Review from the West Bank
  • Peter Bael
  • Zakaria Abu Ghattas
  • Adam Albedd
  • Sandra Istefan
  • Malik Itmaiza
  • Bayan Alqtishat
  • Nizar Qumsieh
  • Tawfeeq Al-Shobaki
  • Hussein Hallak
  • September 1, 2026
  1. Traumatic injury is the seventh leading cause of mortality in Palestine, with significant challenges in trauma care due to ongoing conflict and limited resources.
  2. The study analyzed 1195 trauma patients admitted across four West Bank hospitals from January 2023 to February 2024, with a mean age of 27.13 years.
  3. Blunt trauma accounted for 82.76% of cases, with motor vehicle collisions being the most common cause at 56.65%.
  4. The study reported a case fatality rate of 1.17%, with gunshot injuries contributing significantly to fatalities and extended hospital stays.
  5. The trauma registry in Palestine highlights the need for ongoing documentation of trauma patterns amid the challenges posed by the Israeli occupation.
...more

Emergency Medicine Journal

  • September 1, 2026
Updating Research Priorities in Paediatric Emergency Medicine for the UK and Ireland
  • Charlotte Sloane
  • Thomas Waterfield
  • Jordan Evans
  • Michael Barrett
  • Mark D Lyttle
  • Niall Mullen
  • September 1, 2026

Objective: To update the research priorities for pediatric emergency medicine (PEM) in the UK and Ireland, incorporating perspectives from key stakeholders. App

...more

British Journal Of Ophthalmology

  • September 1, 2026
Malignant Melanocytic Tumors in Clinically Diagnosed Pterygium Cases
  • Rozina Ida Hajdu
  • Paola Kammrath Betancor
  • Othmane Touirssa
  • Claudia Auw-Haedrich
  • Thomas Reinhard
  • Simone Nuessle
  • September 1, 2026
  1. This study investigates malignant melanocytic tumors in surgically removed specimens clinically diagnosed as pterygia.
  2. Seven out of 2,298 specimens (0.30%) showed malignant melanocytic lesions, including four cases of invasive conjunctival melanoma.
  3. Patients with malignant lesions ranged in age from 26 to 71 years, with a median age of 54 years.
  4. The study emphasizes the need for histopathological assessment of all excised pterygia to identify potential malignancies.
  5. Increased clinical awareness is necessary for amelanotic lesions that may be misdiagnosed as pterygium.
...more

Retinal Physician

  • September 1, 2026
Revakinagene for MacTel: Is the Benefit Worth the Cost?
  • Michael Colucciello, MD
  • Martin Friedlander, MD, PhD
  • Kristin Raming, MD
  • September 1, 2026
  • 15 min
  1. Macular telangiectasia type 2 (MacTel) is a rare neurodegenerative condition with a prevalence of 0.045% to 0.1%.
  2. Revakinagene, an encapsulated cell therapy, is the first FDA-approved treatment for MacTel, reducing photoreceptor loss by 55% at 24 months.
  3. Serious adverse events occurred in 5% of patients treated with revakinagene, primarily related to the surgical procedure.
  4. The cost of revakinagene is approximately $250,000, which raises questions about its value compared to other gene therapies.
  5. The discordance between structural preservation and visual function in MacTel complicates the estimation of quality-adjusted life-year gains.
...more

Retinal Physician

  • September 1, 2026
Genetic Testing in Retinoblastoma: New Applications
  • Soumaya Bouhout, MD
  • Arun D. Singh, MD
  • September 1, 2026
  • 9 min

Objective: To explore the expanding role of genetic testing in retinoblastoma, particularly through liquid biopsy and molecular profiling. Approach: Overview of

...more

Retinal Physician

  • September 1, 2026
JIA-Associated Uveitis in Adults
  • Alissa Belzie, MD, MS
  • Ana M. Suelves, MD, PhD
  • September 1, 2026
  • 13 min

Objective: To explore the persistence and complications of juvenile idiopathic arthritis-associated uveitis (JIAU) in adults. Approach: Overview of JIAU: JIAU i

...more

Retinal Physician

  • September 1, 2026
Evolving Treatment Strategies for Noninfectious Uveitis
  • William R. Bloom, MD
  • Ana M. Suelves, MD, PhD
  • September 1, 2026
  • 16 min
  1. Recent advances in treatment for noninfectious uveitis include corticosteroid delivery, systemic immunomodulation, and new pipeline therapies.
  2. Corticosteroids remain the primary treatment for acute ocular inflammation, with local therapies minimizing systemic side effects.
  3. The fluocinolone acetonide 0.19-mg intravitreal implant provides sustained corticosteroid delivery for up to 36 months, improving recurrence rates.
  4. Suprachoroidal triamcinolone acetonide was approved to treat uveitic macular edema, offering targeted therapy with a favorable safety profile.
  5. Biologic agents like adalimumab and infliximab are used for NIU when conventional therapies fail, allowing selective inhibition of inflammatory pathways.
...more

Retinal Physician

  • September 1, 2026
Proteomics in Uveal Melanoma
  • Arun D. Singh, MD
  • Kevin Allan, MD, PhD
  • September 1, 2026
  • 13 min
  1. Proteomics in uveal melanoma may enhance diagnosis, prognostication, and therapeutic discovery through analysis of proteins in blood and ocular fluids.
  2. Nearly 40% of uveal melanoma patients develop metastatic disease despite effective local control, highlighting the need for improved diagnostic methods.
  3. Aqueous humor proteomics can provide insights into tumor characteristics and has shown potential for better sensitivity than conventional liver function tests.
  4. Studies indicate that proteomic signatures in aqueous humor correlate with tumor characteristics, such as size and chromosomal alterations.
  5. Proteomics offers a less invasive alternative to traditional biopsy, allowing for repeated sampling and longitudinal monitoring of uveal melanoma.
...more

Glaucoma Physician

  • September 1, 2026
Procedural Pharmaceutical Lessons From Early Adopters
  • September 1, 2026
  • 18 min

Objective: To share insights from experienced glaucoma surgeons on integrating sustained drug delivery into glaucoma management. Approach: Patient Selection and

...more

Glaucoma Physician

  • September 1, 2026
Is There a Role for SLT After MIGS?
  • Shivani S. Kamat, MD
  • September 1, 2026
  • 13 min

Objective: To evaluate the role of selective laser trabeculoplasty (SLT) in managing intraocular pressure (IOP) after minimally invasive glaucoma surgery (MIGS)

...more

Glaucoma Physician

  • September 1, 2026
Perspectives on Medicare’s Proposed iDose TR Coverage Policy
  • Steven R. Sarkisian, Jr., MD
  • Inder Paul Singh, MD
  • Savak “Sev” Teymoorian, MD, MBA
  • Manjool Shah, MD
  • Christine Funke, MD
  • Philip S. Garza, MD, MSc
  • September 1, 2026
  • 10 min

Objective: To discuss the implications of Medicare's proposed local coverage determinations (LCDs) for iDose TR on patient care and glaucoma treatment practices

...more

Glaucoma Physician

  • September 1, 2026
The Prevention Paradox
  • Nathan Radcliffe, MD
  • September 1, 2026
  • 4 min

Objective: To discuss the paradox of prevention in glaucoma treatment, highlighting the challenges related to patient and payer reluctance to act before visible

...more

Glaucoma Physician

  • September 1, 2026
Letter to Editor and Response
  • Sean Ianchulev, MD, MPH
  • Kevin J. Corcoran, COE, FNAO
  • September 1, 2026
  • 7 min
  1. The May 2026 coding column lacked disclosure of the author's financial relationships relevant to the discussed procedural categories.
  2. Undisclosed reimbursement influence in coding guidance is compared to clinical influence, highlighting a need for transparency.
  3. The author argues that coding guidance impacts physician billing behavior and patient access, particularly for elderly glaucoma patients.
  4. Dr. Ianchulev's letter emphasizes the need for journals to apply disclosure standards to coding instruction as rigorously as clinical content.
  5. The CPT Editorial Panel approved a new Category III code for the AlloFlo Uveo procedure, effective January 1, 2027, addressing existing coding limitations.
...more

Glaucoma Physician

  • September 1, 2026
Beyond Today’s Implants: The Next Generation of Sustained Drug Delivery
  • Ciera D. Johnson, BS
  • Rachel Chapman
  • Samantha Goldburg, MD
  • Mary Qiu, MD,
  • September 1, 2026
  • 12 min
  1. Medication adherence is a significant challenge in glaucoma management, influenced by cost, complex regimens, and cognitive decline.
  2. The FDA-approved iDose TR implant demonstrated sustained IOP reduction and safety through 36 months in clinical studies.
  3. PolyActiva's PA5108 microimplant showed over 20% IOP reduction in phase 2a trials, with no adverse effects on corneal endothelium.
  4. The BIM-IOL system aims to deliver bimatoprost for up to 3 years post-cataract surgery, showing a 34% mean IOP reduction in early studies.
  5. Various investigational drug delivery platforms are being explored, including biodegradable implants and smart contact lenses.
...more

Glaucoma Physician

  • September 1, 2026
Revisiting Strategies for Glaucoma Education
  • Inder Paul Singh, MD
  • September 1, 2026
  • 12 min
  1. Glaucoma is the leading cause of irreversible blindness, with nearly 50% of patients undiagnosed and many unaware of their condition.
  2. Patients with mildly elevated IOP often miss follow-up visits, leading to significant disease progression before they return.
  3. Topical drops are associated with a high rate of nonadherence, with 60% of patients lost to follow-up when managed with them.
  4. Selective laser trabeculoplasty (SLT) is preferred as a first-line therapy for early-stage glaucoma over topical drops.
  5. A proactive approach to glaucoma care, including procedural options, is recommended to prevent disease progression and improve patient outcomes.
...more

Glaucoma Physician

  • September 1, 2026
Predicting Success After Angle Surgery
  • Si Jia Chen, BS
  • Arsham Sheybani, MD
  • September 1, 2026
  • 13 min
  1. Angle-based minimally invasive glaucoma surgery (MIGS) is increasingly used for patients with open-angle glaucoma.
  2. Clinical features such as baseline intraocular pressure (IOP) and medication burden are associated with surgical outcomes.
  3. Combined phacoemulsification and MIGS procedures generally yield more favorable outcomes than standalone MIGS.
  4. Prior selective laser trabeculoplasty (SLT) may indicate treatment-resistant glaucoma and affect MIGS success.
  5. Pseudoexfoliation glaucoma (PXG) may respond better to MIGS than primary open-angle glaucoma (POAG), despite being clinically challenging.
...more

Glaucoma Physician

  • September 1, 2026
Glaucoma Trials Tracker
  • September 1, 2026
  • 14 min

Objective: To provide a comprehensive listing of active interventional clinical trials related to glaucoma. Approach: Reformulated PG324 Ophthalmic Solution: St

...more

Retinal Physician

  • September 1, 2026
Coding for Ocular Tumors
  • Elizabeth Cifers, MBA, MSW, CHC, CPC
  • September 1, 2026
  • 4 min

Objective: To provide guidance on accurate coding for ocular tumors, highlighting the need to distinguish between tumor types. Approach: Definitions of Tumor Ty

...more
2 min